Sign In
Buy COYA
$4.19
+0.110 (+2.70%)
At Close: Jul 31, 2026
These biotechs targeting multiple neurodegenerative diseases
08:15am, Friday, 01'st Dec 2023
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance
Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics
05:45am, Monday, 14'th Aug 2023
Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be appr
Coya Therapeutics stock gains on new data from Alzheimer's study
08:40am, Wednesday, 07'th Jun 2023
Shares of Coya Therapeutics Inc. COYA, +3.33% gained 12% premarket on Wednesday after the clinical-stage biotech company released new data from a study of its investigational therapy COYA 301 in patie
Coya: Outstanding Data In ALS And Alzheimer's Justify Large Upside
07:17pm, Tuesday, 16'th May 2023
Recently, IPO'd Coya has just reported cognition-improving and cognition-stabilizing results in an open label study in Alzheimer's patients with Coya 301. In March 2023, Coya had reported stabilizatio
Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep going
09:53am, Tuesday, 16'th May 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Coya Therapeutics, Inc. (COYA) could be a great choice. It is one of the several stocks that passed through our
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance
Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET
07:44am, Thursday, 23'rd Mar 2023
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg fu
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
01:00pm, Tuesday, 21'st Mar 2023
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance
